Brief: Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
12/01/2026 13:36
Jan 12 (Reuters) - CK Life Sciences Intl (Holdings) Inc 0775.HK: DOGWOOD THERAPEUTICS, INC. ANNOUNCES FINANCING OF UP TO $26.8 MILLION TO PROGRESS HALNEURON® THROUGH PHASE 2B DEVELOPMENT Source text: ID:nGNX3CkQW1 Further company coverage: 0775.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study